SCHEMBL14720840

SCHEMBL14720840

NC(=O)C(Br)c1ccc(Br)cc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.53
APLNR P35414 4/20 0.43
ALDH1A1 P00352 3/20 0.36
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
LMNA P02545 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
MAP2K2 P36507 1/20 0.35
MAP2K1 Q02750 1/20 0.35
PARP1 P09874 1/20 0.35
KDM1A O60341 2/20 0.35
KDM1B Q8NB78 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7471753 0.84 CES2 (0.49) DGAT1ALDH1A1PARP1
SCHEMBL14720245 0.82 DGAT1 (0.53) DGAT1APLNRALDH1A1NPC1RAB9A
SCHEMBL19914018 0.82 DGAT1 (0.44) DGAT1APLNRALDH1A1NPC1RAB9A
SCHEMBL18839300 0.81 DGAT1 (0.51) DGAT1APLNRALDH1A1NPC1RAB9A
SCHEMBL14720336 0.78 APLNR (0.47) DGAT1APLNRALDH1A1NPC1RAB9A
SCHEMBL14720140 0.78 LMNA (0.43) DGAT1APLNRALDH1A1NPC1RAB9A
SCHEMBL8217389 0.78 DGAT1 (0.49) DGAT1APLNRALDH1A1NPC1RAB9A
SCHEMBL7477905 0.78 PDE2A (0.53) ALDH1A1GAAKDM4E
SCHEMBL7474529 0.77 DGAT1 (0.33) DGAT1CA1CA2
SCHEMBL18839443 0.77 DGAT1 (0.47) DGAT1APLNRALDH1A1MAP2K2MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2744333-B1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2016-10-05 EP disclosed
US-9084794-B2 Fatty acid synthase inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2015-07-21 US disclosed
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property (No2) Limite (GB) 2014-07-10 US disclosed
EP-2744333-A1 FATTY ACID SYNTHASE INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2014-06-25 EP disclosed
WO-2013028447-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194415-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS2, FADS1 DGAT1 93/4885APLNR 907/4885ALDH1A1 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.